Printer Friendly

POTENTIAL FOR HYAL PRODUCTS IN HEART DISEASE: PREVENTION OF RESTENOSIS TARGETED BY HYAL'S DRUG DELIVERY TECHNOLOGY

 MISSISSAUGA, Ontario, Oct. 19 /PRNewswire/ -- Hyal Pharmaceutical Corporation (NASDAQ-NMS: HYALF) today disclosed results of exploratory research presented at Hyal's first International Workshop on the mechanism of its Hyaluronic Acid (HA) based drug delivery technology.
 Included in these presentations were results from two independent academic centers which showed that new experimental formulations using Hyal's technology were able to inhibit the processes causing restenosis of arteries after balloon angioplasty in animal models. Balloon angioplasty is a medical procedure aimed at opening coronary arteries which are obstructed with cholesterol plaque. Restenosis is the re- blocking of arteries after balloon angioplasty. Each year in the United States, approximately 400,000 patients undergo balloon angioplasty to prevent angina and heart attacks. In 30 percent to 35 percent of the cases, the blockage (restenosis) recurs within six months of treatment. The resulting need for repeat angioplasties or coronary bypass surgery due to restenosis adds more than $2 billion to U.S. healthcare costs.
 Studies conducted at the Manitoba Institute of Cell Biology, University of Manitoba, demonstrated that several days after injury of carotid arteries (caused by balloon angioplasty), rabbits treated with Hyal's experimental formulations could not be differentiated from uninjured control animals. Studies from the William Harvey Research Institute in London, England using cholesterol fed rabbits showed that Hyal's experimental formulations significantly inhibited the thickening of the arterial wall after balloon injury as compared to untreated control animals. Studies, showing enhanced HA receptor expression in response to the injury caused by angioplasty, provide additional evidence for the targeting characteristics of Hyal's drug delivery technology. While these results are preliminary in nature, they suggest the potential for a pipeline of products utilizing Hyal's technology for treatment of cardiovascular related diseases.
 The Hyal sponsored workshop was held in England and was attended by 24 scientists and clinical investigators from seven countries who represent the leading edge of research in both HA and NSAID's. The proceedings of this workshop will be edited by Professor D.A. Willoughby of the William Harvey Institute and published early in 1994 by the Royal Society of Medicine.
 Hyal is currently conducting Phase III clinical trials at a total of 20 independent centers in Canada, the U.S.A., Australia and a number of European countries for its three lead products: HYAL-CT1101 for the treatment of basal cell carcinoma and actinic keratosis, HYAL-AT2101 for the topical treatment of chronic pain and HYAL-AV2201 for the intravenous treatment of moderate to severe pain. Hyal's basal cell carcinoma and topical pain products are in Phase III U.S. trials.
 Hyal specializes in the development and worldwide commercialization of pharmaceutical formulations utilizing its proprietary Hyaluronic Acid based drug delivery technology. Hyal Pharmaceutical Corporation's shares are traded on the Toronto Stock Exchange under the trading symbol HPC and on NASDAQ National Market System under the trading symbol HYALF.
 -0- 10/19/93
 /CONTACT: Samuel S. Asculai, Ph.D., president & CEO, 416-366-4863 or David W. Harper, VP - development of Hyal, 416-366-4863; or Diane Perry, 212-661-8030 or Kathy Brunson, 312-366-7800, both of The financial Relations Board/
 (HYALF)


CO: Hyal Pharmaceutical Corporation ST: Ontario IN: MTC SU:

WB -- NY072 -- 4018 10/19/93 13:28 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 19, 1993
Words:524
Previous Article:INTERNATIONAL TRADING COMPANY NAMES MEXICAN NATIONAL TO HEAD MEXICO CITY OPERATION
Next Article:LISC/NEF ANNOUNCE $1.5 BILLION COMMUNITY RENEWAL COMMITMENT; CLEVELAND TO RECEIVE $30 MILLION TO DEVELOP HOUSING AND REVITALIZE COMMUNITY
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters